Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,720.97
    +1,487.47 (+3.02%)
     

  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

BUZZ-BTG: drugmaker beats on sales, but Varithena underwhelms

Reuters - UK Focus

** BTG (LSE: BTG.L - news) retreats from 14-yr highs hit recently, down 3 pct & 3rd-top FTSE 250 faller

** Brokers flag 3 pct FY15 sales beat, but Varithena (co's pioneering varicose vein treatment) sales just 1 mln pounds vs estimates of c.5 mln pounds

** Jefferies remains optimistic on long-term outlook, saying US Varithena feedback encouraging but its initial sales could stall share price momentum

** Jefferies rated at 5 stars for recommendation accuracy on BTG, according to StarMine

** Stock c.9 pct below 14-yr high hit mid-Jan; Varithena had been lifting shares (up c.40 pct in 2014) (RM (LSE: RM.L - news) : tricia.wright1.thomsonreuters.com@reuters.net)